MRP Capital Investments LLC Purchases 16,185 Shares of Amedisys, Inc. (NASDAQ:AMED)

MRP Capital Investments LLC lifted its position in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 448.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,795 shares of the health services provider's stock after purchasing an additional 16,185 shares during the period. Amedisys comprises 2.1% of MRP Capital Investments LLC's portfolio, making the stock its 10th largest position. MRP Capital Investments LLC owned 0.06% of Amedisys worth $1,882,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in AMED. Prudential Financial Inc. raised its holdings in Amedisys by 2.5% in the first quarter. Prudential Financial Inc. now owns 3,728 shares of the health services provider's stock valued at $643,000 after acquiring an additional 90 shares in the last quarter. Commonwealth Equity Services LLC raised its holdings in Amedisys by 2.9% in the third quarter. Commonwealth Equity Services LLC now owns 3,896 shares of the health services provider's stock valued at $364,000 after acquiring an additional 110 shares in the last quarter. Xponance Inc. raised its holdings in Amedisys by 3.2% in the third quarter. Xponance Inc. now owns 4,076 shares of the health services provider's stock valued at $381,000 after acquiring an additional 125 shares in the last quarter. Arizona State Retirement System increased its stake in Amedisys by 1.5% during the third quarter. Arizona State Retirement System now owns 9,284 shares of the health services provider's stock valued at $867,000 after purchasing an additional 141 shares during the last quarter. Finally, Covestor Ltd increased its stake in Amedisys by 88.9% during the first quarter. Covestor Ltd now owns 323 shares of the health services provider's stock valued at $56,000 after purchasing an additional 152 shares during the last quarter. 94.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have weighed in on AMED shares. Raymond James reiterated a "market perform" rating on shares of Amedisys in a research note on Tuesday, March 26th. StockNews.com started coverage on shares of Amedisys in a research note on Monday. They set a "buy" rating for the company. Finally, Royal Bank of Canada boosted their target price on shares of Amedisys from $97.00 to $100.00 and gave the company an "outperform" rating in a research note on Monday, March 25th. Seven research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $97.50.

Amedisys Price Performance

AMED traded down $0.37 on Friday, reaching $91.90. The company had a trading volume of 157,142 shares, compared to its average volume of 283,340. The company has a fifty day moving average of $93.05 and a 200-day moving average of $93.50. The company has a market capitalization of $3.00 billion, a P/E ratio of -296.44, a PEG ratio of 4.34 and a beta of 0.86. The company has a current ratio of 1.05, a quick ratio of 1.05 and a debt-to-equity ratio of 0.32. Amedisys, Inc. has a one year low of $73.10 and a one year high of $96.44.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its earnings results on Wednesday, February 21st. The health services provider reported $0.94 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.04 by ($0.10). The company had revenue of $570.79 million during the quarter, compared to the consensus estimate of $566.85 million. Amedisys had a negative net margin of 0.44% and a positive return on equity of 12.76%. The business's quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.16 EPS. As a group, equities research analysts anticipate that Amedisys, Inc. will post 4.54 earnings per share for the current year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc. (NASDAQ:AMED - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.